Cell Cycle / Checkpoint Control
|
| CSTコード | 包装 | 希望納入価格（円） |
国内在庫  2010年7月30日15時15分 現在 |
|
|---|---|---|---|---|
| #2524 | 100 μL | 46,000 | ログインすると国内在庫状況がご確認いただけます。
|
|
推奨プロトコール 最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。 注：各製品に最適化されたプロトコールをリンクしています。 |
|---|
| 用途 (希釈倍率) | |
|---|---|
| ウェスタンブロッティング (1:1,000)、免疫沈降 (1:500)、免疫蛍光細胞染色 (IF-IC) (1:1,000) | |
| 種交差性 | |
|---|---|
| ヒト、マウス、ラット、サル | |
| 特異性・感度 | |
|---|---|
| 内在性レベルのp53 タンパク質を検出します。 | |
| 検出タンパク質の分子量 | |
|---|---|
| 53 kDa | |
| 使用抗原 | |
|---|---|
| ヒトのp53 タンパク質のSer20 周辺領域 (合成ペプチド) | |
| 抗体の由来 | |
|---|---|
| マウス | |
| 貯法 | |
|---|---|
| -20℃ | |
| 社内データ |
|---|
Western Blotting
Western blot analysis of extracts from A431, COS, NBT-II and JB6 cells, untreated or UV-treated, using p53 (1C12) Mouse mAb.
Western Blotting
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence ® Control siRNA (Fluorescein Conjugate) #6201 (-) or SignalSilence ® p53 siRNA I (+), using p53 (1C12) Mouse mAb and p42 MAPK (Erk2) Antibody #9108. p53 (1C12) Mouse mAb confirms silencing of p53 expression, while the p42 MAPK (Erk2) Antibody is used to control for loading and specificity of p53 siRNA.
Western Blotting
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence ® Control siRNA (Fluorescein Conjugate) #6201 (-) or SignalSilence ® p53 siRNA II (+), using p53 (1C12) Mouse mAb and β-Actin (13E5) Rabbit mAb #4970. p53 (1C12) Mouse mAb confirms silencing of p53 expression, while the β-Actin (13E5) Rabbit mAb is used to control for loading and specificity of p53 siRNA.
IF-IC
Confocal immunofluorescent analysis of HT-29 cells using p53 (1C12) Mouse mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red).
| バックグラウンド |
|---|
The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (5,6). p53 can be phosphorylated by ATM, ATR and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,7). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability and activity (8,9). p53 is phosphorylated at Ser392 in vivo (10,11) and by CAK in vitro (11). Phosphorylation of p53 at Ser392 is increased in human tumors (12) and has been reported to influence the growth suppressor function, DNA binding and transcriptional activation of p53 (10,13,14). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both in vitro and in vivo (13,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) in vivo to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).
- Levine, A.J. (1997) Cell 88, 323-331.
- Meek, D.W. (1994) Semin. Cancer Biol. 5, 203-210.
- Milczarek, G.J. et al. (1997) Life Sci. 60, 1-11.
- Shieh, S.Y. et al. (1997) Cell 91, 325-334.
- Chehab, N.H. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 13777-13782.
- Honda, R. et al. (1997) FEBS Lett. 420, 25-27.
- Tibbetts, R.S. et al. (1999) Genes Dev. 13, 152-157.
- Shieh, S.Y. et al. (1999) EMBO J. 18, 1815-1823.
- Hirao, A. et al. (2000) Science 287, 1824-1827.
- Hao, M. et al. (1996) J. Biol. Chem. 271, 29380-29385.
- Lu, H. et al. (1997) Mol. Cell. Biol. 17, 5923-5934.
- Ullrich, S.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 5954-5958.
- Kohn, K.W. (1999) Mol. Biol. Cell 10, 2703-2734.
- Lohrum, M. and Scheidtmann, K.H. (1996) Oncogene 13, 2527-2539.
- Knippschild, U. et al. (1997) Oncogene 15, 1727-1736.
- Oda, K. et al. (2000) Cell 102, 849-862.
- Ito, A. et al. (2001) EMBO J. 20, 1331-1340.
- Sakaguchi, K. et al. (1998) Genes Dev. 12, 2831-2841.
- Solomon, J.M. et al. (2006) Mol. Cell. Biol. 26, 28-38.
| 使用例 | |
|---|---|
| 製品をご使用いただいて研究を発表されましたら、ぜひお知らせください。 |
本製品は試験研究用です。
